Phase 2 Study of Cabazitaxel in Refractory Metastatic Gastric and Gastroesophageal Adenocarcinoma

Diseases and Conditions Researched

Esophagus; Other Digestive Organ

What is the purpose of this trial?

To demonstrate the antitumor activity as assessed by the rate of progression free survival at three
months of the sanofi-aventis product cabazitaxel 25mg/m2 IV over 1 hour every 3 weeks in subjects
with previously treated metastatic gastroesophageal adenocarcinoma who are either taxane naïve, or
taxane previously treated

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Weill Medical College of Cornell University
Last Updated:
Study HIC#: 1312013191